COYA
HealthcareCoya Therapeutics, Inc.
$5.36
$-0.29 (-5.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Coya Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $112.16M. The company has 8 employees and is classified as a small-scale business within its industry. It has generated revenue of $3.99M over the trailing twelve months (TTM) but incurred significant losses, resulting in net income of -$18,433,340 and EBITDA of -$20,061,276. The company's financial health is marked by significant losses, with gross margins at -244.3%, operating margins at -53.8%, and a profit margin of 0.0%. Returns on equity (ROE) and assets (ROA) are also negative, standing at -62.2% and -37.1%, respectively. The company's balance sheet is characterized by a significant amount of cash, totaling $28.13M, while debt information is not available. The valuation context for Coya Therapeutics, Inc. is marked by a negative earnings per share (EPS) ratio, with a forward P/E of -3.29 and an EV/EBITDA of -4.49. The company's price to book ratio stands at 3.29, and its price to sales ratio is 28.13. Dividend information is not applicable, given the absence of dividend payments.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Visit website →Key Statistics
- Market Cap
- $112.16M
- P/E Ratio
- N/A
- 52-Week High
- $8.29
- 52-Week Low
- $4.65
- Avg Volume
- 230.74K
- Beta
- 0.26
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 8